Paradigm Biopharma - Termination of coverage
Edison Investment Research is terminating coverage on Atlantis Japan Growth Fund (AJG), Paradigm Biopharma (PAR), The European Smaller Companies...
317 Views
Australian Biotech Companies Amid Talk of Likely Interest Rate Cut
RBA keeps interest rates steady at 4.35%, while economists predict possible cut to 4.10% in 4Q24. Australian biotech companies should be in focus...
291 Views
Paradigm Biopharma - Q1 results recap iPPS progress in OA & MPS
Paradigm announced Q1 results (for the quarter ending 30 September) and a A$30m capital raise to potentially extend its cash runway through to mid...
406 Views
Paradigm Biopharma - Disease modifying properties in iPPS Phase II
Paradigm reported favourable quantitative MRI data from the six-month analysis of the Phase II trial (PARA OA 008) evaluating a single six-week...
258 Views
Paradigm Biopharmaceuticals (PAR AU): Positive Result from Phase 2 Trial; Satisfactory Cash Position
Phase 2 trial shows that iPPS treats osteoarthritis symptoms as well as preserves/regenerates joint tissues, potentially leading to greater...
359 Views